Clinical Trial Search

Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61

Primary: Number of Participants With Adverse Events — 6; 14; 53; 10 participants

Primary: Short-term End Point — 61; 77 participants

Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12

Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18

Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts

Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47

Primary: Number of Subjects With Adverse Events — 7; 4 Participants

Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…

Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio

Primary: Average Subject Time Spent on Cardiopulmonary Cross Clamp — 77.5; 82.0 Minutes — p=0.3660

Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants

Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts

Primary: Freedom From Aortic Insufficiency More Than 2+ (Percentage, Kaplan-Meier) — 88.2; 87.7 percentage of participants

Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants

Primary: Percentage of MAE Free Subjects — 10 Participants

Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion

Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…

Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L

Primary: Subject's Percentage of Long Term Safety Performance — 1.5; 2.7; 0.2; 0.4 Percentage of events/late patient years

Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days

Primary: Generic Mental Health-Related Quality of Life — 50.0; 46.2; 57.2 units on a scale

Primary: MACCE — 80; 51 Participants — p=0.35

Primary: Vein Graft Intimal Area — 4.1; 4.5 mm

Primary: Cognitive Function — 0.07; 0.12 Continuous cognitive change score

Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded

Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects

Primary: Late Adverse Event Rates — 1.90; 0; 2.61; 0.12 percentage of events/late patient years

Primary: Short Physical Performance Battery — 7.33; 8.00; 11.44; 10.90 units on a scale

Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2